

# 173rd ACNFP Meeting

## Executive Summary

- Urolithin A RP1777– The Committee reviewed this novel food application for the first time, an ingredient for use in foods and food supplements. Information gaps were identified across identity, production process, composition, stability, specifications, ADME and toxicology. The Secretariat was advised to seek further information from the applicant to complete the assessment. The CAD will be updated in due course and reviewed at the next available meeting.
- Three separate CBD applications were reviewed for the first time: RP47, RP46 and RP225 (reserved business). For the applications RP47 and RP46, information gaps were identified with respect to the toxicological information for both CBD novel foods. The Secretariat was advised to seek further information from these applicants. For the application RP225, the CAD was agreed with minor edits. This output will proceed to publication.
- An introduction to Group C CBD applications was provided by the Secretariat to the Committee. This covered risk assessment approaches and data requirements for hemp extracts containing a significant amount of CBD present (group C). The feedback was noted by the Secretariat, and this will inform the management of individual applications as they brought for Committee review.
- Workshop on Cell Cultivated Products (CCP) (reserved business) – the Committee was presented with a draft supplementary FSA applicant guidance document developed by the FSA Sandbox Team. The developed section of the guidance covered the nutrition and allergenicity assessments for CCPs. The Committee provided feedback, and this input will be taken forward into the continued development of this guidance document.
- *Clostridium tyrobutyricum* ‘Clostridium Protein’ RP1920 – the Committee reviewed this novel food application for the first time, a microbial protein ingredient intended for use in a wide range of foods. Information gaps were identified across identity, production process, composition and stability, specifications, proposed uses and anticipated Intake, ADME, nutrition and allergenicity. Concerns were raised with regards to proposed use levels

which did not align with the provided toxicological data. The Secretariat was advised to seek further information from the applicant to complete the assessment. The CAD will be updated in due course and reviewed at the next available meeting.

- Lyso-phosphatidylcholine (LPC)-rich oil from Antarctic krill (*Euphausia superba*) RP2181 – the Committee reviewed this novel food application for the first time, an alternative krill oil food supplement as a source of omega-3 long chain polyunsaturated fatty acids and bioavailable LPC. Information gaps were identified across composition, specifications, ADME and toxicology. The Secretariat was advised to seek further information from the applicant to complete the assessment. The CAD will be updated in due course and reviewed at the next available meeting.
- One GM item was reviewed as reserved business: GMB151 x DAS-44406-6 soybean RP2246. The assessment was finalised following a detailed review by the PGT-Subcommittee. The respective CAD was agreed with minor edits. This output will proceed to publication.

## Agenda

[173rd Meeting of the ACNFP 24th & 25th September 2025 Agenda](#)

## Minutes

[Minutes of the 173rd Meeting held on the 24th and 25th September 2025](#)

## Meeting Papers

[Urolithin A](#)

[Clostridium Tyrobutyricum \(Clostridium Protein\)](#)

[Lyso-Phosphatidylcholine \(LPC\) -Rich Oil from Antarctic Krill Euphausia Superba](#)